DCAT Value Chain Insights’ Production to Prescription
DCAT
51 episodes
2 weeks ago
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023
DCAT Value Chain Insights’ Production to Prescription
23 minutes
2 years ago
CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023
As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterLarge-scale biomanufacturing expansions continue Samsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLo...
DCAT Value Chain Insights’ Production to Prescription
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
